To this end, mice with TAA-induced liver fibrosis were injected intravenously (i.v.)with the hepatotropic serotype 8 AAV vectors expressing the murine miR-34b or miR-34c under the control of the hepatocyte-specific thyroxine-binding globulin (TBG) promoter to potentiate the anti-fibrotic effect of miR-34c produced by hepatocytes that do not overexpress the miR-34c under TAA-induced liver fibrosis (Figure S3). The gene discussed is SERPINA7; the disease is Hepatic fibrosis.